Category : Search result: Aurobindo Pharma stock


Stock Under Rs 50 Gains 297%, Hits Upper Circuit

A small-cap stock priced under Rs 50 delivered a staggering 297% return in one year, hitting the upper circuit as Indian markets rallied in early trade. Discover the details and key drivers behind this surge.

Aurobindo Pharma buys Khandelwal Labs unit for ₹325 cr

Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.

Aurobindo Pharma increases stake in China JV to 50%

Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.

India Pharma Targets $500B, Innovation Hub by 2047

India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.

Sonipat Trader Held in Rs 118 Cr GST Evasion Case

CGST Rohtak arrests Sonipat pharma trader Pawel Garg for alleged GST evasion of Rs 21.30 crore on sales of Rs 118.49 crore. Raid uncovers unaccounted transactions. Read the full details.

Rajit Kapur's Malayalam comeback after 25 years

National Award-winning actor Rajit Kapur discusses his return to Malayalam cinema with the medical drama 'Pharma', his role as Dr. Rajiv Rao, and the rise of South Indian OTT content.

Sun Pharma Shares Fall 3% Post-US FDA Inspection

Sun Pharmaceutical shares fell over 3% after a US FDA inspection at its Baska plant. The inspection concluded with 3 observations. Get the full details on the market impact and company's response.

Odisha Approves Pharma & Medtech Policy 2025

Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.

Granules India's US facility passes FDA GMP inspection

Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.

Sun Pharma's Ilumya for Psoriasis Launched in India

Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.

Page 1 of 4